NASDAQ:CYCCPCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.50 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$5.50Now: $5.50▼$5.5050-Day Range$5.48MA: $6.16▼$7.7552-Week Range$3.87Now: $5.50▼$8.07VolumeN/AAverage Volume713 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.12%BetaN/A ProfileAdvanced ChartCompetitorsDividendEarningsFinancialsHeadlinesSEC FilingsSocial Media Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs. Previous Next 2.5 Community Rank Outperform VotesCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs has received 97 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs has received 95 “underperform” votes. (Add your “underperform” vote.)Community SentimentCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs has received 50.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs and other stocks. Vote “Outperform” if you believe CYCCP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYCCP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs has a dividend yield of 0.12%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthCyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYCCP Previous Symbol CUSIPN/A CIK1130166 Webwww.cyclacel.com Phone+1-908-5177330Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable NASDAQ:CYCCP Rates by TradingView Receive CYCCP News and Ratings via Email Sign-up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (NASDAQ:CYCCP) Frequently Asked Questions How has Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock been impacted by COVID-19 (Coronavirus)? Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock was trading at $6.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYCCP stock has decreased by 10.6% and is now trading at $5.50. View which stocks have been most impacted by Coronavirus. How often does Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs? Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs announced a quarterly dividend on Wednesday, July 1st. Stockholders of record on Friday, July 17th will be paid a dividend of $0.15 per share on Saturday, August 1st. This represents a $0.60 dividend on an annualized basis and a dividend yield of 10.91%. The ex-dividend date of this dividend is Thursday, July 16th. View Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' dividend history. Has Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs been receiving favorable news coverage? Media headlines about CYCCP stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs. Who are some of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key competitors? Some companies that are related to Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE) and Canada House Wellness Group (CHV). View all competitors. Who are Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' key executives? Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' management team includes the following people: Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 60)Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 58)Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 59)Ms. Gill Christie, Director of HR (Age 62)Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 75) What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock symbol? Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs trades on the NASDAQ under the ticker symbol "CYCCP." How do I buy shares of Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs? Shares of CYCCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' stock price today? One share of CYCCP stock can currently be purchased for approximately $5.50. What is Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' official website? The official website for Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs is www.cyclacel.com. How can I contact Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs? Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs' mailing address is 200 Connell Dr Ste 1500, BERKELEY HEIGHTS, NJ 07922-2811, United States. The company can be reached via phone at +1-908-5177330. This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
